Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO Creating "Game-Changing" Legislative Proposal To Boost R&D

Executive Summary

BIO's blueprint for an economic and regulatory environment that facilitates innovation in biotechnology and the industry's ability to bring products to market could be finished within a few months.

You may also be interested in...

BIO's "Big Ideas" Include Expanding FDA's Mission, Allowing "Progressive Approval"

FDA would no longer just be tasked with protecting public health but also with encouraging product development under ambitious legislative proposals that BIO is set to reveal.

BIO Teams With Zerhouni On Quest For "New Big Ideas" To Speed Development

BIO CEO Jim Greenwood is looking for "new big ideas" that would enable the pharmaceutical industry "to accelerate the pace of progress from academic research and translational research into products.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts